ProQR
 | This article, ProQR, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Inform author |
ProQR Therapeutics NV is a Dutch biotechnology company based in Leiden, the Netherlands. ProQR was founded in 2012 by CEO Daniel de Boer and co-founders Henri Termeer[1][2][3], Dinko Valerio[3][4], Gerard Platenburg[3][4]. The company’s current pipeline includes RNA treatments for rare genetic diseases[5] including Leber's congenital amaurosis[5][6], dystrophic epidermolysis bullosa[5][6] and Usher syndrome[7].
References
- ^ Weisman, Robert (January 20, 2018). "Henri Termeer isn't exactly settling into retirement". The Boston Globe.
- ^ McBride, Ryan (May 10, 2013). "Henri Termeer rediscovers the 'Genzyme feel' in world of biotech startups". FierceBiotech.
- ^ a b c Carroll, John (Sep 9, 2014). "Termeer-backed ProQR lays out terms for $75M IPO". FierceBiotech.
- ^ a b Taylor, Nick Paul (Sep 13, 2017). "ProQR spins out CNS assets to form RNA rare disease biotech". FierceBiotech.
- ^ a b c Rodríguez Fernández, Clara (March 12, 2018). "A Dutch Company on the Quest Against Cystic Fibrosis". LaBiotech.eu.
- ^ a b Rossi, Krista (May 25, 2018). "Daniel de Boer, CEO of ProQR, Explains RNA Treatment, QR-313, for DEB". Rare Disease Report.
- ^ Dale, Alex (Feb 13, 2018). "ProQR Tackles Blindness Caused by a Rare". LaBiotech.eu.
 | This Dutch corporation or company article is a stub. You can help Wikipedia by expanding it. |
| This article, ProQR, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Inform author |